Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy

Enrollment was stopped early because of a low ctDNA-positivity rate (8% of 1,901 tested; 5.2% on the first test) and a high rate of radiographic recurrence already present at first ctDNA positivity (72/147, 49%). Among the 40 randomized patients, median DFS was 11.4 months with niraparib vs 5.4 months with placebo (HR 0.64, 95% CI 0.30-1.39), a comparison the sample size cannot support as a conclusive efficacy result. No new safety signals for niraparib were reported.

San Antonio Breast Cancer Symposium 2024